{
  "id": "3840ad51164c93fa",
  "title": "FDA approves Breyanzi for relapsed , refractory marginal zone lymphoma",
  "description": "20251216T024500Z",
  "content": "",
  "source": "medicalxpress.com",
  "source_url": "https://medicalxpress.com/news/2025-12-fda-breyanzi-relapsed-refractory-marginal.html",
  "published_at": "20251216T024500Z",
  "fetched_at": "2025-12-17T00:22:43.797460+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda"
  ],
  "location": "United States",
  "raw_data": {
    "url": "https://medicalxpress.com/news/2025-12-fda-breyanzi-relapsed-refractory-marginal.html",
    "url_mobile": "",
    "title": "FDA approves Breyanzi for relapsed , refractory marginal zone lymphoma",
    "seendate": "20251216T024500Z",
    "socialimage": "https://scx2.b-cdn.net/gfx/news/2025/fda-approves-breyanzi.jpg",
    "domain": "medicalxpress.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}